Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation
Completed · Phase 3 · Has a placebo group
Conditions studied: Cytomegalovirus Infections
In brief
The study evaluated the efficacy and safety of a prolonged, continuous course of Valganciclovir (Valgan) in the prevention of CMV by comparing 3 months of Vaglanciclovir, the standard of care upon initiation of the study, to 12 months of Valganciclovir.
Key facts
- Study ID
- NCT00227370
- Run by
- Duke University
- People needed
- 136
- Starts
- 2003-07-01
- Expected to finish
- 2008-12-01
- Last updated by the study team
- 2024-10-04
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- DukeUMC — Durham, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.